Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer

M. A. Cobleigh, Kathy Miller, V. K. Langmuir, J. D. Reimann, A. V. Vassel, W. F. Novotny, G. W. Sledge

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Breast cancer is known to produce vascular endothelial growth factor (VEGF), a key molecule in the regulation of angiogenesis. Increased VEGF protein and mRNA levels are associated with decreased overall and disease-free survival. It follows that inhibition of VEGF production may slow tumor growth and lead to longer survival. Therefore, a Phase II dose escalation trial of a recombinant humanized monoclonal antibody to VEGF (bevacizumab; rhuMAb VEGF) was undertaken. Methods: Seventy-five women with previously treated metastatic breast cancer were treated with Avastin at 3 mg/ kg (n=18), 10 mg/kg (n=41) or 20 mg/kg (n=16) IV every 2 weeks until progression. The endpoints of the trial were safety, best objective response rate and pharmacokinetics. Results: The median age of patients in this trial was 48 years and patients had received a median of two prior chemotherapy regimens for metastatic disease. The median duration of treatment was 10 weeks. Dose-limiting toxicity was headache (Grade 3 in 1; Grade 4 in 1) associated with nausea and vomiting which occurred in 4 patients treated at 20 mg/kg. Four patients discontinued study participation because of adverse events: 1 with hypertensive encephalopathy and nephrotic syndrome at 3 mg/kg, 1 with proteinuria at 10 mg/kg, 1 with nephrotic syndrome at 20 mg/kg and 1 with severe headache, nausea and vomiting at 20 mg/kg. 7 of 75 (9.3%) patients had an objective response including 1 CR in a supraclavicular node at 10 mg/kg that recurred 3 months after completing 1 year of therapy. PR occurred in 6 patients (2 unconfirmed) with disease in lymph nodes, skin, pleura, bone and liver. Median duration of confirmed response was 5.6 months. Responders had smaller tumor burden, lower ECOG status and higher albumin at baseline than the overall population. 12 of 75 (17%) patients had an ongoing response or stable disease at the last tumor assessment at 5 months. Three patients were treated for one year or longer without disease progression. Median survival was 10.2 months. Conclusions: Avastin monotherapy results in objective response or disease stabilization in a significant number of patients. Adverse events of significance included hypertension and proteinuria. A Phase III trial combining Avastin with capecitabine is currently underway.

Original languageEnglish
Pages (from-to)301
Number of pages1
JournalBreast Cancer Research and Treatment
Volume69
Issue number3
StatePublished - 2001
Externally publishedYes

Fingerprint

Breast Neoplasms
Vascular Endothelial Growth Factor A
Nephrotic Syndrome
Proteinuria
Nausea
Vomiting
Headache
Hypertensive Encephalopathy
Antibodies, Monoclonal, Humanized
Bevacizumab
Survival
Pleura
Tumor Burden
Disease-Free Survival
Disease Progression
Albumins
Neoplasms
Pharmacokinetics
Lymph Nodes
Hypertension

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cobleigh, M. A., Miller, K., Langmuir, V. K., Reimann, J. D., Vassel, A. V., Novotny, W. F., & Sledge, G. W. (2001). Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer. Breast Cancer Research and Treatment, 69(3), 301.

Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer. / Cobleigh, M. A.; Miller, Kathy; Langmuir, V. K.; Reimann, J. D.; Vassel, A. V.; Novotny, W. F.; Sledge, G. W.

In: Breast Cancer Research and Treatment, Vol. 69, No. 3, 2001, p. 301.

Research output: Contribution to journalArticle

Cobleigh, MA, Miller, K, Langmuir, VK, Reimann, JD, Vassel, AV, Novotny, WF & Sledge, GW 2001, 'Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer', Breast Cancer Research and Treatment, vol. 69, no. 3, pp. 301.
Cobleigh, M. A. ; Miller, Kathy ; Langmuir, V. K. ; Reimann, J. D. ; Vassel, A. V. ; Novotny, W. F. ; Sledge, G. W. / Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer. In: Breast Cancer Research and Treatment. 2001 ; Vol. 69, No. 3. pp. 301.
@article{ee31b0684a234ab09c6a0e1e3da53ca1,
title = "Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer",
abstract = "Breast cancer is known to produce vascular endothelial growth factor (VEGF), a key molecule in the regulation of angiogenesis. Increased VEGF protein and mRNA levels are associated with decreased overall and disease-free survival. It follows that inhibition of VEGF production may slow tumor growth and lead to longer survival. Therefore, a Phase II dose escalation trial of a recombinant humanized monoclonal antibody to VEGF (bevacizumab; rhuMAb VEGF) was undertaken. Methods: Seventy-five women with previously treated metastatic breast cancer were treated with Avastin at 3 mg/ kg (n=18), 10 mg/kg (n=41) or 20 mg/kg (n=16) IV every 2 weeks until progression. The endpoints of the trial were safety, best objective response rate and pharmacokinetics. Results: The median age of patients in this trial was 48 years and patients had received a median of two prior chemotherapy regimens for metastatic disease. The median duration of treatment was 10 weeks. Dose-limiting toxicity was headache (Grade 3 in 1; Grade 4 in 1) associated with nausea and vomiting which occurred in 4 patients treated at 20 mg/kg. Four patients discontinued study participation because of adverse events: 1 with hypertensive encephalopathy and nephrotic syndrome at 3 mg/kg, 1 with proteinuria at 10 mg/kg, 1 with nephrotic syndrome at 20 mg/kg and 1 with severe headache, nausea and vomiting at 20 mg/kg. 7 of 75 (9.3{\%}) patients had an objective response including 1 CR in a supraclavicular node at 10 mg/kg that recurred 3 months after completing 1 year of therapy. PR occurred in 6 patients (2 unconfirmed) with disease in lymph nodes, skin, pleura, bone and liver. Median duration of confirmed response was 5.6 months. Responders had smaller tumor burden, lower ECOG status and higher albumin at baseline than the overall population. 12 of 75 (17{\%}) patients had an ongoing response or stable disease at the last tumor assessment at 5 months. Three patients were treated for one year or longer without disease progression. Median survival was 10.2 months. Conclusions: Avastin monotherapy results in objective response or disease stabilization in a significant number of patients. Adverse events of significance included hypertension and proteinuria. A Phase III trial combining Avastin with capecitabine is currently underway.",
author = "Cobleigh, {M. A.} and Kathy Miller and Langmuir, {V. K.} and Reimann, {J. D.} and Vassel, {A. V.} and Novotny, {W. F.} and Sledge, {G. W.}",
year = "2001",
language = "English",
volume = "69",
pages = "301",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Phase II dose escalation trial of Avastin™ (bevacizumab) in women with previously treated metastatic breast cancer

AU - Cobleigh, M. A.

AU - Miller, Kathy

AU - Langmuir, V. K.

AU - Reimann, J. D.

AU - Vassel, A. V.

AU - Novotny, W. F.

AU - Sledge, G. W.

PY - 2001

Y1 - 2001

N2 - Breast cancer is known to produce vascular endothelial growth factor (VEGF), a key molecule in the regulation of angiogenesis. Increased VEGF protein and mRNA levels are associated with decreased overall and disease-free survival. It follows that inhibition of VEGF production may slow tumor growth and lead to longer survival. Therefore, a Phase II dose escalation trial of a recombinant humanized monoclonal antibody to VEGF (bevacizumab; rhuMAb VEGF) was undertaken. Methods: Seventy-five women with previously treated metastatic breast cancer were treated with Avastin at 3 mg/ kg (n=18), 10 mg/kg (n=41) or 20 mg/kg (n=16) IV every 2 weeks until progression. The endpoints of the trial were safety, best objective response rate and pharmacokinetics. Results: The median age of patients in this trial was 48 years and patients had received a median of two prior chemotherapy regimens for metastatic disease. The median duration of treatment was 10 weeks. Dose-limiting toxicity was headache (Grade 3 in 1; Grade 4 in 1) associated with nausea and vomiting which occurred in 4 patients treated at 20 mg/kg. Four patients discontinued study participation because of adverse events: 1 with hypertensive encephalopathy and nephrotic syndrome at 3 mg/kg, 1 with proteinuria at 10 mg/kg, 1 with nephrotic syndrome at 20 mg/kg and 1 with severe headache, nausea and vomiting at 20 mg/kg. 7 of 75 (9.3%) patients had an objective response including 1 CR in a supraclavicular node at 10 mg/kg that recurred 3 months after completing 1 year of therapy. PR occurred in 6 patients (2 unconfirmed) with disease in lymph nodes, skin, pleura, bone and liver. Median duration of confirmed response was 5.6 months. Responders had smaller tumor burden, lower ECOG status and higher albumin at baseline than the overall population. 12 of 75 (17%) patients had an ongoing response or stable disease at the last tumor assessment at 5 months. Three patients were treated for one year or longer without disease progression. Median survival was 10.2 months. Conclusions: Avastin monotherapy results in objective response or disease stabilization in a significant number of patients. Adverse events of significance included hypertension and proteinuria. A Phase III trial combining Avastin with capecitabine is currently underway.

AB - Breast cancer is known to produce vascular endothelial growth factor (VEGF), a key molecule in the regulation of angiogenesis. Increased VEGF protein and mRNA levels are associated with decreased overall and disease-free survival. It follows that inhibition of VEGF production may slow tumor growth and lead to longer survival. Therefore, a Phase II dose escalation trial of a recombinant humanized monoclonal antibody to VEGF (bevacizumab; rhuMAb VEGF) was undertaken. Methods: Seventy-five women with previously treated metastatic breast cancer were treated with Avastin at 3 mg/ kg (n=18), 10 mg/kg (n=41) or 20 mg/kg (n=16) IV every 2 weeks until progression. The endpoints of the trial were safety, best objective response rate and pharmacokinetics. Results: The median age of patients in this trial was 48 years and patients had received a median of two prior chemotherapy regimens for metastatic disease. The median duration of treatment was 10 weeks. Dose-limiting toxicity was headache (Grade 3 in 1; Grade 4 in 1) associated with nausea and vomiting which occurred in 4 patients treated at 20 mg/kg. Four patients discontinued study participation because of adverse events: 1 with hypertensive encephalopathy and nephrotic syndrome at 3 mg/kg, 1 with proteinuria at 10 mg/kg, 1 with nephrotic syndrome at 20 mg/kg and 1 with severe headache, nausea and vomiting at 20 mg/kg. 7 of 75 (9.3%) patients had an objective response including 1 CR in a supraclavicular node at 10 mg/kg that recurred 3 months after completing 1 year of therapy. PR occurred in 6 patients (2 unconfirmed) with disease in lymph nodes, skin, pleura, bone and liver. Median duration of confirmed response was 5.6 months. Responders had smaller tumor burden, lower ECOG status and higher albumin at baseline than the overall population. 12 of 75 (17%) patients had an ongoing response or stable disease at the last tumor assessment at 5 months. Three patients were treated for one year or longer without disease progression. Median survival was 10.2 months. Conclusions: Avastin monotherapy results in objective response or disease stabilization in a significant number of patients. Adverse events of significance included hypertension and proteinuria. A Phase III trial combining Avastin with capecitabine is currently underway.

UR - http://www.scopus.com/inward/record.url?scp=33749104913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749104913&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 301

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -